Close Menu

NEW YORK (360Dx) – VolitionRx reported a second quarter net loss of $3.5 million, or $.13 per share, compared to a net loss of $2.9 million, or $.13 per share, a year ago. The company said it had $16.5 million in cash and cash equivalents on June 30. During the quarter, it initiated regulatory approval for its tests in Taiwan and Singapore, and noted that if it gets approval in Singapore, it would provide VolitionRx access to nine other South Asian markets.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.